|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Results</b>: Adenosine A2A-dopamine D2 receptor (A2AR/D2R) heteromer formation was monitored in caudate from healthy and Parkinson's disease (PD) subjects.
|
31340557 |
2019 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease.
|
12722176 |
2003 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
|
29434188 |
2018 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
|
29908325 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Drd2 is also the primary target of both antipsychotics and Parkinson's disease medications.
|
30604007 |
2019 |
|
Parkinson Disease
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
DRD2 methylation to differentiate dementia with Lewy bodies from Parkinson's disease.
|
31659741 |
2020 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dopamine D2 receptor agonist, Ropinirole, has been found to promote neuroprotection in Parkinson´s disease and restless leg syndrome.
|
31816341 |
2020 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
A dopamine D2 receptor agonist, pramipexole, has been found to elicit neuroprotection in patients with Parkinson's disease and restless leg syndrome.
|
31235613 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
MGD |
Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice.
|
9717839 |
1998 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
MGD |
Absence of opiate rewarding effects in mice lacking dopamine D2 receptors.
|
9252189 |
1997 |
|
Parkinson Disease
|
0.600 |
Therapeutic
|
disease |
CTD_human |
ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
|
8558425 |
1996 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
MGD |
Activity, non-selective attention and emotionality in dopamine D2/D3 receptor knock-out mice.
|
11864730 |
2002 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Among non-Hispanic whites, homozygous carriers of Taq1A DRD2 (rs1800497) polymorphism had an increased risk of PD compared to homozygous wildtype carriers (OR=1.5, 95% CI 1.0-2.3).
|
21663922 |
2011 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
MGD |
Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia.
|
9247268 |
1997 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Antipsychotics and serotoninergic antidepressants may potentially attenuate PD risk, and lithium and bupropion may augment risk, through MAPT, GBA, CCDC62, HIP1R, BDNF, and DRD2 transcription, with MAPT, GBA, and CCDC62 being strongly associated with PD risk in recent meta-analyses.
|
22507762 |
2012 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients.
|
19396436 |
2009 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Further, DRD2 variants have been implicated in Parkinson's disease (PD) and in iatrogenically-induced movement disorders, as well as in certain migraineurs.
|
11256581 |
2000 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in the DRD2 gene may influence the risk of developing PD, thus confirming that the DRD2 gene is a susceptibility locus for PD.
|
10634251 |
2000 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genotype combinations characterized by the presence of two variant genotypes on their corresponding loci revealed that four combinations of GSTT1 null and MnSOD(-9Val) or GST null and MAOB-G or CYP2E1*5B and MAO-B-AG or CYP2E1*5B and DRD2 (Taq1A-het) genotypes in the patients exhibited severalfold higher and significant association with risk to PD.
|
18327668 |
2008 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Human genetic studies also show a significant association of DRD2 polymorphisms with disorders including schizophrenia and Parkinson's disease.
|
29107444 |
2017 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, we suggest that L-DOPA may attenuate the neuropathology of PD by regulating signaling related to DRD2 in neuronal cells under α-syn-induced toxicity.
|
28687316 |
2017 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In the current study, we determined whether a dopamine D2 receptor DNA sequence polymorphism interacts with L-DOPA during motor tasks in patients with Parkinson's disease (PD).
|
23439215 |
2013 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we investigated this effect in Parkinson's disease (PD) patients carrying the DRD2 TaqIA A1 allelic variant.
|
17147698 |
2007 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the present study, we used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced PD mouse model to investigate whether Drd2 could suppress astrocytic NLRP3 inflammasome activation.
|
29786071 |
2018 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the hypothesis that a TaqI repeat fragment length polymorphism in the dopamine D2 receptor gene may be associated with PD.
|
11104188 |
2000 |